Presented at
#ASCO26:
In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results:
nej.md/3RuNe00
Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer
nej.md/4dLeiiW
@ASCO